Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The DYNAMO Study
NCT07698535Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Nov 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Washington. Started Nov 2026; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07698535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07698535.